[Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD]
André J Scheen1, Nicolas Paquot1
1Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Liège, Sart Tilman (B35), B-4000 Liège, Belgique.
Abstract:
Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors (gliflozins), which demonstrated a cardiovascular and renal protection, have profoundly changed the management of patients with type 2 diabetes who are at cardiovascular risk. Nowadays, these antidiabetic medications occupy a preferred position, independently of glucose control. This has been emphasized in the last guidelines of the European Society of Cardiology (ESC) and the joint consensus by the American Diabetes Association and the European Association for the Study of Diabetes (ADA-EASD), both published in 2020. Nevertheless, there are some discrepancies between the two points of view, especially concerning the definition of the patient at cardiovascular risk in primary prevention and the first-choice place still to be reserved to metformin in these patients.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Atherosclerosis III: Management
Heart Failure V: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Cardiomyopathy V: Interprofessional Care


